$184.710
0.000 (0.00%)收盘时
- High
- 184.710
- Open
- 184.710
- VWAP
- —
- Vol
- 0.00
- Mkt Cap
- 16.51B
- Low
- 184.710
- Amount
- 0.00
- EV/EBITDA, TTM
- -26.64
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Analyst Ratings (7)
JP Morgan
$317
2025-04-21
JP Morgan
2025-04-21
目标价
$317
Guggenheim
—
2025-04-16
Guggenheim
2025-04-16
目标价
—
Guggenheim
$348
2025-04-10
Guggenheim
2025-04-10
目标价
$348
RBC Capital
$312
2025-04-07
RBC Capital
2025-04-07
目标价
$312
Citizens Capital Markets
$348
2025-02-28
Citizens Capital Markets
2025-02-28
目标价
$348
估值指标
事件时间线
资讯
6.009-18CNBCMajor Analyst Recommendations for Thursday: Nvidia, Apple, Meta, Coinbase, Alphabet, Nike, CSX, Abercrombie & Fitch, and Others
6.004-07CNBCHere are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Netflix, Bank of America, Meta, Reddit, Microsoft & more
9.003-31NewsfilterBeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
9.003-05BusinesswireTEVIMBRA ist in den USA für die Erstlinienbehandlung von fortgeschrittenem Plattenepithelkarzinom der Speiseröhre in Kombination mit Chemotherapie zugelassen
9.003-04BusinesswireSamenvatting: TEVIMBRA goedgekeurd in de VS voor eerstelijns behandeling van gevorderd oesofageaal plaveiselcelcarcinoom in combinatie met chemotherapie
BGNE FAQ — answered by Alphio AI
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
7 analysts cover BGNE: 6 rate it Buy, 1 Hold and 0 Sell.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。